BTIG reiterates Buy rating on Nektar Therapeutics, $178 price targetTradingView·1 day ago, 10:05 AMNKTR+1.45%
The Identity Crisis Portfolio: Who’s Building the Future and Who’s Faking ItGlobal Report·2 days ago, 11:33 AMXE+12.08%MP+0.80%
Record Revenues at nLIGHT and QuinStreet Mask Biotech Cash Burn Across Diverse U.S. Equity GroupGlobal Report·2 days ago, 10:12 AMNKTR+1.45%FIX-0.84%
Business Models in the Real World: Ginkgo's Transition Pains and the Aggregation of InfrastructureGlobal Report·2 days ago, 09:18 AMDHI+1.49%KLAG+2.43%
The Infrastructure Pivot: Repurposing Assets for the Next ParadigmGlobal Report·2 days ago, 07:01 AMCYPH+25.82%SIRI-2.87%
Nektar Therapeutics (NKTR) Lands Lancet Backing, Is The Upside Already Priced In?Simplywall·Sep 6 at 04:22 PMNKTR+1.45%
Braidwell LP Acquires 250,916 Shares of Nektar Therapeutics $NKTRMarket Beat·Sep 3 at 08:40 AMNKTR+1.45%
Peer‑Reviewed REZOLVE‑AD Phase 2b Data Could Be A Game Changer For Nektar Therapeutics (NKTR)Simplywall·Aug 31 at 04:16 PMNKTR+1.45%
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NKTR Stock NewsStockTitan·Aug 28 at 12:15 PMNKTR+1.45%
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic DermatitisUnusual Whales·Aug 25 at 12:33 PMNKTR+1.45%
Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 186 Shares of StockMarket Beat·Aug 21 at 01:08 AMNKTR+1.45%
NKTR: REZPEG phase III trials advance with strong cash position and high physician enthusiasm for novel MOAQuartr·Aug 13 at 11:22 PMNKTR+1.45%
NKTR: Rezpegaldesleukin advanced to Phase 3, with robust cash reserves and narrowed Q2 net lossQuartr·Aug 13 at 08:35 PMNKTR+1.45%
Nektar Q2 2026 Earnings: Phase 3 Spending Rises as Cash and Investments Top $1 BillionTradingKey·Aug 13 at 08:24 PMNKTR+1.45%
